Pancreatic Cancer Five-Year Survival Rate and What It Means For You

Advocacy groups note that pancreatic cancer is the only major cancer with a five-year survival rate below 20 percent, a figure that has barely moved in decades and sits far below the average for all cancers combined.

Advocacy groups note it is the only major cancer with a five-year survival rate below 20%. The five-year relative survival rate compares people with the disease to people of the same age in the general population; it is an average across every stage and health level, not a prediction for any one person, and it does not mean patients live only five years.

Statistics describe groups, and people are individuals, the Cure Today analysis notes, pointing to survivors such as Dan, who moved from a stage 4 diagnosis to long-term survival. The analysis also notes that an individual’s outlook depends on their stage, their tumor’s features, their overall health and how they respond to treatment.

Stage at diagnosis rewrites the outlook entirely. Only 17 percent of cases are caught while the cancer is still localized to the pancreas. For that group, five-year survival jumps to 44 percent — more than three times the overall rate.

That difference is why oncologists focus so intently on whether a tumor is resectable, meaning it can be removed surgically, often through a Whipple procedure. If surgery is not possible up front, chemotherapy may shrink the tumor enough to make it operable later.

Should you be uncertain about your cancer’s stage or whether surgery is an option now or following chemotherapy, request that your oncologist explain it to you.

The disease remains the third leading cause of cancer death in the United States. An estimated 52,740 people will die of pancreatic cancer in 2026, behind only lung and colorectal cancers. Advocacy groups emphasize it is the only major cancer with a five-year survival rate below 20 percent.

That mortality burden is why researchers and advocates are pushing for better treatments, and why the report urges patients to ask about palliative care at diagnosis. Palliative care is specialized symptom management for pain, weight loss and fatigue; it runs alongside disease-directed treatment and is not the same as hospice.

Today’s survival statistics inevitably lag behind today’s treatments. The numbers are built from patients diagnosed years ago, so they cannot reflect therapies approved since.

During 2026, the FDA gave the green light to Rasonque, a first-in-class targeted therapy for metastatic pancreatic cancer, and Cure Today has recorded a case of a patient who switched from chemotherapy to Rasonque. Separate research on a device called Optune Pax showed it delayed pain in locally advanced disease, focusing on quality of life while living with the cancer.

Clinical trials are another pathway. Many experts encourage patients to ask about trials early — at diagnosis and again whenever treatment changes — rather than waiting until standard options are exhausted. The American Cancer Society’s 2026 data, released in January, shows that every percentage point in the survival tables represents people making those decisions right now.